For an explanation of "Laptop session" , Meet-the Expert session" and "Clinical Challenges for Diagnosis" look at the end of the program.
|
Thursday 2 September 2010 |
|
|
16.30 |
Opening ceremony |
| Chairs: J.W.M. van der Meer, The Netherlands & A. Simon, The Netherlands | |
| 16.30 | Opening |
| J.W.M. van der Meer, The Netherlands | |
| 16.45 | Deficiency of Interleukin-1 receptor antagonist (DIRA) |
| I. Aksentijevich, USA | |
| 17.30 | Art lecture |
| Gary Schwartz, Art historian | |
|
19.00 |
Walking dinner |
|
|
|
|
Friday 3 September 2010 |
|
|
08.00 |
Breakfast Meet-the-Expert session 1 |
| Clinical Phenotype of FMF | |
| A. Livneh, Israel & M. Tunca, Turkey | |
|
Breakfast Meet-the-Expert session 2 |
|
| Clinical Phenotype of HIDS | |
| J.W.M. van der Meer, The Netherlands & J. Frenkel, The Netherlands, A. Prieur, France | |
|
Breakfast Meet-the-Expert session 3 |
|
| Basic science Studying inflammasome | |
| S. Masters, Ireland & V. Hornung, Germany | |
|
09.00 |
Plenary session: FMF + PAPA |
| Chairs: E. Ben-Chetrit, Israel & D. Kastner, USA | |
| 09.00 | Environmental effects in FMF |
| S. Özen, Turkey | |
| 09.30 | Regulation of MEFV gene expression |
| I. Touitou, France | |
| 10.00 | The Effect of Colchicine on Pyrin-PSTPIP1 Interaction |
| Z.E. Taskiran, Turkey | |
| 10.15 | Peripheral blood mononuclear cell (PBMC) cultures of M694V homozygous FMF patients reveal a predisposition to secrete high levels of IL-17 given a T cell activation signal. |
| Y. Shinar, Israel | |
|
10.30 |
Coffee break |
|
11.00 |
Plenary session: Oral presentations FMF + PAPA |
| Chairs: E. Ben-Chetrit, Israel & D. Kastner, USA | |
| 11.00 |
The effect of H. Pylori eradication in colchicine-resistant Familial Mediterranean Fever (FMF) Patients |
| G. Hakobyan, Armenia | |
| 11.15 | Validation of the newly developed pediatric criteria for the diagnosis of Familiar Mediterranean fever in a large pediatric cohort of western European children with periodic fever |
|
S. Federici, Italy |
|
| 11.30 | Is familial mediterranean fever (FMF) associated with non-alcoholic fatty liver disease(NAFLD)? |
| M. Rozenbaum, Israel | |
| 11.45 | Analysis of MEFV exon methylation and expression patterns in familial mediterranean fever |
| E.T. Turanli, Turkey | |
| 12.00 | Lunch |
| 12.00 | Laptop presentations |
| 13.00 |
Plenary session: Clinical challenges for diagnosis: plenary discussion with expert panel |
| Chair: J.P.H. Drenth, The Netherlands | |
| Speakers panel discussion: | |
|
H. Yazici, Turkey, E. Ben-Chetrit,
Israel, P. Hawkins, UK, D. Kastner, USA, J.W.M. van der Meer, The Netherlands |
|
| 14.30 |
Plenary session: HIDS + TRAPS + PFAPA |
| Chairs: J. Frenkel, The Netherlands & M. Gattorno, Italy | |
| 14.30 | IgD and immune surveillance |
| A. Cerutti, USA | |
| 15.00 | Adenotonsillectomy in PFAPA as first-line treatment: yes or no? |
| M. Hofer, Switzerland | |
| 15.30 | Analysis of an unfolded protein response and reactive oxygen species generation as a disease mechanism of TRAPS |
| J. Dickie, UK | |
| 15.45 |
Reactive Oxygen Species Potentiate LPS-Mediated
Inflammation in the TNF Receptor-Associated Periodic Syndrome (TRAPS) |
| A.C.B. Bulua, USA | |
| 16.00 | Discussion |
| 16.15 | Tea break |
| 16.45 |
Plenary session: Oral presentations HIDS + TRAPS + PFAPA |
| Chairs: J. Frenkel, The Netherlands & M. Gattorno, Italy | |
| 16.45 | TRAPS associated mutations affect a multitude of intracellular pathways beyond the canonical TNFR1 pathways through alterations in both protein abundance and signalling response dynamics. |
|
P.J. Tighe, UK |
|
| 17.00 | PFAPA Syndrome – a systems biology approach reveals activation of the innate and adaptive immunity with responsiveness to IL-1ß blockade |
|
S. Stojanov, Germany |
|
| 17.15 | TLR2/TLR4-dependent aberrant IL-1 signaling in hyperimmunoglobulinemia D and periodic fever syndrome (HIDS) |
|
M. Stoffels, The Netherlands |
|
| 17.30 | Role for Rac1 signaling in the development of autoinflammatory disease |
|
R. Van der Burgh, The Netherlands |
|
|
Saturday 4 September 2010 |
|
|
08.00 |
Breakfast Meet-the-Expert session 4 |
| All about genetics | |
| I. Touitou, France & J.P.H. Drenth, The Netherlands | |
|
Breakfast Meet-the-Expert session 5 |
|
| Clinical Phenotype of CAPS | |
| R. Goldbach-Mansky, USA & H. Hoffman, USA | |
|
Breakfast Meet-the-Expert session 6 |
|
| Basic Science Studying Cytokines | |
| M. Netea, The Netherlands & C. Dinarello, USA | |
|
09.00 |
Plenary session: Regulation of innate immunity |
| Chairs: C. Dinarello, USA & M. Netea, The Netherlands | |
| 09.00 | Dissecting IL-1 and caspase activation |
| T. Kanneganti, USA | |
| 09.30 | Inflammasome activation by dsDNA |
| V. Hornung, Germany | |
| 10.00 | Inflammasome activation |
| G. Guarda, Switzerland | |
|
10.30 |
Inflammasome-dependent and -independent activation of IL-1beta |
| M. Netea, The Netherlands | |
|
11.00 |
Coffee break |
|
11.30 |
Plenary session: Oral presentations Regulation of innate immunity |
| Chairs: C. Dinarello, USA & M. Netea, The Netherlands | |
| 11.30 | Temperature sensitive TRP channels in human peripheral blood mononuclear cells. |
| M. Stoffels, The Netherlands | |
| 11.45 | Endothelial-derived secondary necrotic apoptotic bodies release biologically active IL-1alpha |
| P. Kaplanski, France | |
| 12.00 | Pattern recognition receptors in normal and inflamed human epidermis: upregulation of dectin-1 in psoriasis |
| H.D. de Koning, The Netherlands | |
| 12.15 | Do NALP3 play a role in cytoplasmatic HIV recognition and dendritic cells activation, linking innate to specific immunity in HIV infection? |
| A. Pontillo, Italy | |
|
|
|
| 12.30 | Lunch |
| 12.30 | Laptop presentations |
| 13.30 | Workshop 1 |
| Basic science issues in the lab: how to measure inflammasome activation / IL-1 processing? | |
|
Chair: H. Waterham, The Netherlands Speakers panel discussion: C. Dinarello, USA, M. Netea, The Netherlands, A. Rubartelli, Italy |
|
| Workshop 2 | |
| International Patient Registries | |
|
Chair: J. Frenkel, The Netherlands Speakers panel discussion: M.Gattorno (Eurofever), Italy, H. Lachmann (Eurotraps), UK, M. Hofer (PFAPA), Switzerland, H. de Koning (Schnitzler), The Netherlands |
|
| 14.30 | Plenary session: Autoinflammation versus autoimmunity |
| Chair: J.P.H. Drenth, The Netherlands | |
| Panel members: D. Kastner, D. McGonagle, J. Cohen Tervaert & J. van der Meer | |
| 16.00 |
Tea break |
| 16.30 |
Plenary session: CAPS / DIRA / NALP12 |
| Chairs: R. Goldbach-Mansky, USA & H. Hoffman, USA | |
| 16.30 | In vivo IL-1 beta regulation in CAPS |
| H. Lachmann, UK | |
| 17.00 | Long-term followup of anakinra in CAPS |
| R. Goldbach-Mansky, USA | |
| 17.30 | Rilonacept in CAPS |
| H. Hoffman, USA | |
| 18.00 |
Coffee break |
| 18.15 |
Plenary session: Oral presentations CAPS / DIRA / NALP12 |
| Chairs: R. Goldbach-Mansky, USA & H. Hoffman, USA | |
| 18.15 | Functional consequences of a germline mutation in the leucin rich repeat domain of NLRP3 identified in an atypical autoinflammatory disorder |
|
I. Jéru, France |
|
| 18.30 | Hearing loss in Muckle-Wells-Syndrome – effects of IL-1 inhibition |
| J.B. Kuemmerle-Deschner, Germany | |
| 18.45 |
Initial characterization of a mouse model of neonatal onset multisystem inflammatory disease |
| D. Brydges, USA | |
| 19.00 | A redox signature shared by NLRP3-mutated and NLRP12-mutated monocytes causes accelerated secretion of IL-1ß. |
| A. Rubartelli, Italy | |
| 20.00 | Congress dinner |
|
|
|
|
Sunday 5 September 2010 |
|
|
08.30 |
Workshop 3 |
| Animal Models for diseases | |
| Chair: H. Waterham, The Netherlands | |
| Mouse model FMF | |
| J. Chae, USA | |
| Mouse model CAPS | |
| S. Brydges, USA | |
| Mouse model HIDS | |
| H. Waterham, The Netherlands & M. Gibson, USA | |
| Mouse model CRMO | |
| P. Ferguson, USA | |
| Mouse model TRAPS | |
| R. Siegel, USA | |
|
Workshop 4 |
|
| Genetics: quality control and genetic tests | |
| Chair: I. Touitou, France | |
| Panel members: | |
|
I. Aksentijevich, USA |
|
| Y. Shinar, Israel | |
|
J. Arostegui, Spain |
|
|
10.00 |
Coffee break |
|
10.30 |
Plenary session: Other systemic autoinflammatory diseases |
| Chairs: J.W.M. van der Meer, The Netherlands & H. Yazici, Turkey | |
| 10.30 | Treatment of Behcet’s disease |
| H. Yazici, Turkey | |
| 11.00 | The EMBO lecture: Heart failure as a reactive autoinflammatory disease |
| C. Dinarello, USA | |
| 11.30 |
Classification of Immunological Disease-Focus on MHC Class 1 intermediate disorders |
| D. McGonagle, UK | |
| 12.00 |
Plenary session: Oral presentations Other systemic autoinflammatory diseases |
| Chairs: J.W.M. van der Meer, The Netherlands & H. Yazici, Turkey | |
| 12.00 | IL-18 Binding protein (il-18bp) dramatically improves liver histological lesions in an animal model of macrophage activation syndrome (mas). |
| P. Kaplanski, France | |
| 12.12 | PED-BD: An international cohort study on pediatric Behçet’s disease: One-year data of 110 patients |
| I. Koné-Paut, France | |
| 12.24 | Granulomas in NOD2-related Pediatric Granulomatous Arthritis and Crohn’s Disease: an Immunohistochemical Study. |
| C.E.I. Janssen | |
| 12.36 | Mapping dynamic protein interactions of Receptor Interacting Protein 2 (RIP2) and ProCaspase-1 by co-immunoprecipitation and life-cell imaging |
| S.R. Hofmann, Germany | |
| 12.48 | Clinical phenotype and CARD15 gene mutation with Blau Syndrome in Chinese children and their parents |
| C.F. Li, China | |
| 13.00 | Lunch |
| 13.00 | Laptop presentations |
| 14.30 | Plenary session: Developments in treatment and diagnostics |
| Chairs: H. Lachmann, UK & S. Özen, Turkey | |
| 14.30 | S100A12 protein |
| H. Wittkowski, Germany | |
| 15.00 | Alpha1-antitrypsin |
| C. Dinarello, USA | |
| 15.30 | Developments in IL-1 inhibition |
| H. Lachmann, UK | |
| 16.00 | Tea break |
| 16.30 | Plenary session: Oral presentations Developments in treatment and diagnostics |
| Chairs: H. Lachmann, UK & S. Özen, Turkey | |
| 16.30 | Colchicine does not decrease the need for immunosuppressive use at long term in behçet’s syndrome (bs) |
|
G. Hatemi, Turkey |
|
| 16.42 | Safe, Rapid-onset, and Sustained Biological Activity of IL-1ß Regulating Antibody XOMA 052 in Resistant Uveitis of Behçet’s Disease: Preliminary Results of a Pilot Trial |
| A. Gul, Turkey | |
| 16.54 |
The role of montelukast in the management of hyperimmunoglobulinemia D
with periodic fever syndrome(HIDS) |
| P. Goldsmith, USA | |
| 17.06 |
Experience with anakinra in 120 patients with systemic autoinflammatory diseases |
| A. Melo Gomes, Portugal | |
| 17.18 |
On demand rather than continuous anakinra treatment is effective in mevalonate kinase deficiency |
| E.J. Bodar, The Netherlands | |
| 17.30 | Plenary session: Oral presentations New Genes and Late Break-through |
| Chairs: A. Simon, The Netherlands & D. Kastner, USA | |
| 17.30 |
Functional human protein analysis in the post-genome era learning to new autoinflammatory syndrome (Nakajo-Nishimura syndrome) |
| H. Ida, Japan | |
| 17.45 | Identification of the mutation predisposing to a periodic fever syndrome in Chinese Shar-Pei dogs |
|
M. Olsson, Sweden |
|
| 18.00 |
A novel autoinflammatory syndrome with lymphedema (aisle) |
| G. Hatemi, Turkey | |
| 18.15 |
Genome-wide Association Study Identifies Common Variants of the IL10 and IL23R Genes that Contribute to Behçet’s Disease Susceptibility |
| F. Remmers, USA | |
| Monday 6 September 2010 | |
|
08.00 |
Breakfast Meet-the-Expert session 7 |
| Clinical Phenotype of TRAPS | |
| R. Powell, UK & P. Hawkins, UK | |
|
Breakfast Meet-the-Expert session 8 |
|
| Treatment of FMF | |
| H. Ozdogan, Turkey & E. Pras, Israel | |
|
Breakfast Meet-the-Expert session 9 |
|
| Clinical Phenotype of PFAPA | |
| M. Hofer, Switzerland & S. Stojanov, USA | |
| 09.00 | Plenary session: Amyloidosis, other long-term complications and prognosis |
| Chairs: B. Hazenberg, The Netherlands & P. Hawkins, UK | |
| 09.00 | New insights development of AA amyloidosis |
| J. van der Hilst, The Netherlands | |
| 09.30 | Pharmacological depletion of SAP |
| P. Hawkins, UK | |
| 10.00 | Atherosclerosis and the inflammasome in DM type 2 |
| S. Masters, Ireland | |
| 10.30 | Coffee break |
| 11.00 | Plenary session: Oral presentations Amyloidosis, other long-term complications and prognosis |
| Chairs: B. Hazenberg, The Netherlands & P. Hawkins, UK | |
| 11.00 |
Evaluation of autonomic nervous system dysfunction in FMF patients, with and without amyloidosis |
| U. Nussinovitch, Israel | |
| 11.15 |
Causes and predictiors of death and prognosis in familial mediterranean fever in the colchicine era |
| G. Can, Turkey | |
| 11.30 |
AA Amyloidosis Complicating the Inherited Periodic Fever Syndromes |
| T. Lane, UK | |
| 11.45 | Closing plenary session |
| Chairs: J. Frenkel, The Netherlands & J.W.M. van der Meer, The Netherlands | |
| 11.45 | 3 best laptop presentations |
| 12.15 | Closing session |
| D. Kastner, USA | |
| 12.45 | Closing |
| A. Simon, The Netherlands | |
|
Clinical Challenges for Diagnosis
Establishing the diagnosis of a
specific autoinflammatory disease can be very challenging. A few of such
diagnostic challenges will be presented to teams of renowned clinicians
that will try to solve them during a public discussion on Saturday
September 4. You are kindly invited to provide us with complicated
cases, where a diagnosis has been reached, or as yet unsolved cases.
Please contact us (e.erren@
congresscare.com) if you have a suitable case in mind. It is possible to
stay anonymous if you prefer, since the aim is purely to examine the
diagnostic process in a potential case of autoinflammatory disease.
Laptop sessions
The usual poster sessions will be substituted by laptop
sessions. Instead of bringing a printed-out poster, each laptop
presenter will bring his/her own laptop. In the designated area, each
presenter will be assigned a standing-table where he or she can talk
their audience through their work, using approximately 5 powerpoint
slides. The audience will have the opportunity to walk freely between
the several laptop presenters. We hope this setup will encourage
face-to-face interaction and discussion. For participants who have no
laptop, we will provide a small number of laptops on location - please
let us know in advance if you need this.
Meet-the-expert-sessions
These are informal and interactive sessions. The invited
experts may prepare a short presentation if they want to, but the main
goal of these sessions is to get a chance to ask questions, discuss
dilemmas and exchange ideas.
|